INTRODUCTION {#s1}
============

Laryngeal cancer (LC) is a common type of malignant head and neck tumor, and the incidence is increasing yearly \[[@R1]\]. However, the etiology of LC remains unclear and the prognosis is poor. LC can result from both environmental and genetic factors \[[@R2], [@R3]\]. While the majority of LC patients have a history of smoking and alcohol consumption \[[@R4]\], only a small percentage of individuals with similar histories eventually develop LC. This suggests that genetic susceptibility underlies LC \[[@R5]\].

Host genetic factors may influence the prognosis of cancer patients. Recently, various genetic polymorphisms were associated with a risk of LC \[[@R6]--[@R9]\]. Polymorphisms may contribute to cancer susceptibility, progression, and response to therapy. Previous studies have primarily assessed associations between single nucleotide polymorphisms (SNPs) and LC risk using case-control models. Rare host genetic factors that influence the prognosis of advanced LC patients have been reported. Long-term longitudinal studies are required to evaluate the impact of SNPs on disease progression, treatment response, and patient survival.

In this study, we investigated 37 SNPs in 27 genes that were previously associated with head and neck cancers to determine whether they were associated with the prognosis of LC patients.

RESULTS {#s2}
=======

The demographic and clinical characteristics of the LC patients are shown in Table [1](#T1){ref-type="table"}. The median age of the patients was 60 years (range, 32--82). All of the patients were men who were metastasis-free. The mean follow-up period was 38 months (range: 3--122). There were 100 deaths at the time of the last observation. Overall, the median survival time was 48 months.

###### Characteristics of patients included in this study

  Variables                                           *N* (%)       *p* value
  --------------------------------------------------- ------------- -----------
  Total number of patients enrolled                   170           
  Age                                                               \> 0.05
   \< 60                                              80 (47.06)    
   ≥ 60                                               90 (52.94)    
  Tumor differentiation                                             \> 0.05
   Well                                               31 (18.24)    
   Moderate                                           125 (73.53)   
   Poor                                               14 (8.23)     
  pT                                                                \< 0.001
   T1                                                 40 (23.53)    
   T2                                                 62 (36.47)    
   T3                                                 50 (29.41)    
   T4                                                 18 (10.59)    
  pN                                                                \< 0.001
   N0                                                 116 (68.23)   
   N1                                                 30 (17.65)    
   N2                                                 24 (14.12)    
  WHO grade                                                         \< 0.001
   I                                                  37 (21.76)    
   II                                                 36 (21.18)    
   III                                                61 (35.88)    
   IV                                                 36 (21.18)    
  Surgery method                                                    \< 0.001
   Partial laryngectomy                               104 (61.18)   
   Total laryngectomy                                 66 (38.82)    
  Cervical lymph node dissection                                    \> 0.05
   Yes                                                37 (21.76)    
   No                                                 133 (78.24)   
  No. patients with follow-up information available   170           
   Median follow-up time, months                      38            
   Median survival time, months                       48            
  Status at last observation                                        
   Alive                                              70 (41.18)    
   Death                                              100 (58.82)   

T, pathologic tumor stage; N, pathologic nodal stage.

Clinical factors including age, pT, pN, WHO grade, degree of tumor differentiation, surgical method, and whether the patient underwent cervical lymph node dissection were assessed in a univariate analysis (Table [2](#T2){ref-type="table"}). The distribution of the studied SNPs in the WHO grade was listed in [Supplementary Table S1](#SD2){ref-type="supplementary-material"}. We identified significant associations between clinical factors including the degree of tumor differentiation, pT, pN, WHO grade, and surgical method and LC patient prognosis. All of these factors increased the risk of mortality. Compared to patients with T1--T2 stage disease, N0, I--II grade, and who underwent partial laryngectomy, patients with T3--T4 stage, N1--N2, III--IV grade, and who underwent total laryngectomy had elevated risks of death, with HRs and 95% CIs of 2.17 (1.448--3.253), 2.394 (1.582--3.623), 3.298 (2.100--5.180) and 2.346 (1.576--3.492), respectively (Figure [1](#F1){ref-type="fig"}).

###### Univariate analysis of the impact of clinical factors on prognosis for LC patients

  Variables                        Overall survival                                 
  -------------------------------- ------------------ ------ ---------------------- ----------
  Age                                                                               
   \< 60                           47/80              59.0   Ref                    
   ≥ 60                            53/90              48.0   1.161 (0.782--1.722)   0.456
  Tumor differentiation                                                             
   Well                            18/31              71.0   Ref                    
   Moderate                        70/125             59.0   0.933 (0.556--1.567)   0.008
   Poor                            12/14              15.0   2.397 (1.150--4.997)   
  pT                                                                                
   T1--T2                          52/102             77.0   Ref                    
   T3--T4                          48/68              32.0   2.170 (1.448--3.253)   \< 0.001
  pN                                                                                
   N0                              61/116             71.0   Ref                    
   N1-N2                           39/54              26.0   2.394 (1.582--3.623)   \< 0.001
  WHO grade                                                                         
   I--II                           30/73              98.0   Ref                    
   III--IV                         70/97              32.0   3.298 (2.100--5.180)   \< 0.001
  Surgery method                                                                    
   Partial laryngectomy            50/104             73.0   Ref                    
   Total laryngectomy              50/66              30.0   2.346 (1.576--3.492)   \< 0.001
  Cervical lymph node dissection                                                    
   Yes                             19/37              36.0   Ref                    
   No                              81/133             56.0   0.711 (0.425--1.189)   0.188

T, pathologic tumor stage; N, pathologic nodal stage;

MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval.
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The basic characteristics of all candidate SNPs that were analyzed in the study, including chromosome, position, band, alleles A/B, gene(s), and role(s), are shown in Table [3](#T3){ref-type="table"}. Two of the 37 candidate SNPs evaluated showed statistically significantly correlations with overall survival (Table [4](#T4){ref-type="table"}) according to Log-rank tests and Cox regression analysis. The A/G genotype of *alcohol dehydrogenase 1B (ADH1B)* rs1042026 (HR, 0.538; 95% CI, 0.345--0.839) and G/A genotype of rs1229984 (HR, 0.659; 95% CI, 0.438--0.991) were associated with increased overall survival. Kaplan-Meier curves of overall survival for the different genotypes of rs1042026 and rs1229984 are shown in Figure [2](#F2){ref-type="fig"}.

###### Candidate SNP data

  SNP ID       Chr   Position    Band       Alleles A/B   Gene(s)        Role
  ------------ ----- ----------- ---------- ------------- -------------- -------------------
  rs13130787   4     94887031    4q22.2     T/C                          
  rs3805322    4     100056998   4q23       G/A           *ADH4*         Intron
  rs1042026    4     100228466   4q23       A/G           *ADH1B*        3′ UTR
  rs1229984    4     100239319   4q23       G/A           *ADH1B*        Coding exon
  rs1789924    4     100274286   4q23       T/C           *ADH1C*        Promoter
  rs971074     4     100341861   4q23       A/G           *ADH7*         Coding exon
  rs1000589    13    64141913    13q21.31   G/T                          
  rs1585440    13    66481815    13q21.32   A/C                          
  rs9573163    13    73908846    13q22.1    C/G                          
  rs9543325    13    73916628    13q22.1    T/C                          
  rs1886449    13    73932114    13q22.1    T/C                          
  rs2039553    13    80299722    13q31.1    G/A                          
  rs944289     14    36649246    14q13.3    T/C                          
  rs4444235    14    54410919    14q22.2    C/T           *BMP4*         Downstream
  rs4779584    15    32994756    15q13.3    C/T           *SCG5*         Downstream
  rs4785204    16    50103734    16q12.1    T/C           *HEATR3*       Intron
  rs9929218    16    68820946    16q22.1    A/G           *CDH1*         Intron
  rs17761864   17    2171637     17p13.3    A/C           *SMG6*         Intron
  rs4924935    17    18753870    17p11.2    C/T           *PRPSAP2*      Promoter
  rs225190     17    30877658    17q11.2    G/A           *MYO1D*        Intron
  rs6503659    17    39897264    17q21.2    A/T           *HAP1*         Promoter
  rs2257205    17    56448297    17q22      A/G           *RNF43*        Coding exon
  rs2847281    18    12821593    18p11.21   C/T           *PTPN2*        Intron
  rs12456874   18    13366862    18p11.21   G/A           *C18orf1*      Intron
  rs4939827    18    46453463    18q21.1    T/C           *SMAD7*        Intron
  rs7504990    18    50517776    18q21.2    T/C           *DCC*          Intron
  rs961253     20    6404281     20p12.3    A/C                          
  rs2423279    20    7812350     20p12.3    C/T                          
  rs4925386    20    60921044    20q13.33   T/C           *LAMA5*        Intron (boundary)
  rs372883     21    30717737    21q21.3    G/A           *BACH1*        Intron
  rs455804     21    31146169    21q21.3    T/G           *NCRNA00110*   Downstream
  rs2014300    21    36357861    21q22.12   A/G           *RUNX1*        Intron
  rs1547374    21    43778895    21q22.3    G/A           *TFF1*         Downstream
  rs4822983    22    29115066    22q12.1    T/C           *CHEK2*        Intron
  rs738722     22    29130012    22q12.1    T/C           *HSCB*         Promoter
  rs2239815    22    29192670    22q12.1    T/C           *XBP1*         Intron
  rs5768709    22    48929569    22q13.32   A/G           *FAM19A5*      Intron

A/B, minor/major alleles; Chr, chromosome.

###### Univariate analysis of the associations between the candidate SNPs and LC patient survival

  SNP ID       Genotype   Event/total   MST (months)   HR (95% CI)             Log-rank *p*
  ------------ ---------- ------------- -------------- ----------------------- --------------
  rs13130787                                                                   
               C/C        19/38         98             Ref                     
               T/C        71/113        39             1.638 (0.986--2.722)    0.152
               T/T        10/19         62             1.414 (0.656--3.049)    
  rs3805322                                                                    
               A/A        22/39         73             Ref                     
               G/A        59/98         44             0.982 (0.601--1.604)    0.997
               G/G        19/33         50             0.981 (0.529--1.818)    
  rs1042026                                                                    
               G/G        30/40         31             Ref                     
               A/G        58/114        81             0.538 (0.345--0.839)    0.001
               A/A        3/4           8              2.344 (0.709--7.741)    
  rs1229984                                                                    
               A/A        39/54         36             Ref                     
               G/A        57/104        48             0.659 (0.438--0.991)    0.043
               G/G        2/9                          0.291 (0.070-1.206)     
  rs1789924                                                                    
               C/C        95/158        46             Ref                     
               T/C        4/11          84             0.542 (0.198--1.481)    0.222
               T/T                                                             
  rs971074                                                                     
               G/G        73/125        50             Ref                     
               A/G        26/44         46             1.118 (0.714--1.751)    0.624
               A/A                                                             
  rs1000589                                                                    
               T/T        42/66         38             Ref                     
               G/T        38/77         68             0.691 (0.444--1.075)    0.003
               G/G        20/26         22             1.711 (0.997-2.937)     
  rs1585440                                                                    
               C/C        23/33         62             Ref                     
               A/C        75/134        48             0.803 (0.502--1.286)    0.595
               A/A        1/2           11             1.299 (0.174--9.683)    
  rs9573163                                                                    
               G/G        30/59         62             Ref                     
               C/G        56/92         40             1.397 (0.896--2.180)    0.113
               C/C        14/19         36             1.882 (0.996--3.558)    
  rs9543325                                                                    
               C/C        33/47         35             Ref                     
               T/C        47/86         66             0.691 (0.443--1.080)    0.200
               T/T        20/37         59             0.674 (0.386--1.176)    
  rs1886449                                                                    
               C/C        6/11          77             Ref                     
               T/C        75/131        48             1.193 (0.518--2.746)    0.898
               T/T        2/2           20             1.365 (0.266--6.991)    
  rs2039553                                                                    
               A/A        32/58         81             Ref                     
               G/A        19/32         32             1.474 (0.832--2.612)    0.389
               G/G        19/36         62             1.075 (0.607--1.902)    
  rs944289                                                                     
               C/C        16/26         62             Ref                     
               T/C        79/137        50             0.712 (0.414--1.223)    0.068
               T/T        2/3           6              2.792 (0.638--12.221)   
  rs4444235                                                                    
               T/T        25/34         40             Ref                     
               C/T        63/115        59             0.762 (0.479--1.211)    0.506
               C/C        6/11          84             0.859 (0.352--2.098)    
  rs4779584                                                                    
               T/T        65/103        48             Ref                     
               C/T        30/57         62             0.805 (0.521--1.242)    0.611
               C/C        5/10          44             0.905 (0.363--2.256)    
  rs4785204                                                                    
               C/C        51/87         46             Ref                     
               T/C        32/54         59             1.002 (0.643--1.560)    0.803
               T/T        10/16         37             1.248 (0.631--2.467)    
  rs9929218                                                                    
               G/G        70/118        48             Ref                     
               A/G        27/48         73             0.855 (0.548--1.334)    0.081
               A/A        2/2           14             3.931 (0.946--16.324)   
  rs17761864                                                                   
               C/C        75/120        46             Ref                     
               A/C        16/37                        0.660 (0.384--1.133)    0.087
               A/A        3/4           7              2.282 (0.714--7.297)    
  rs4924935                                                                    
               T/T        80/130        44             Ref                     
               C/T        13/28         98             0.596 (0.331--1.074)    0.110
               C/C        5/7           32             1.578 (0.635--3.920)    
  rs225190                                                                     
               A/A        54/96         62             Ref                     
               G/A        40/65         44             1.137 (0.754--1.715)    0.634
               G/G        4/6           18             1.528 (0.551--4.238)    
  rs6503659                                                                    
               T/T        73/123        56             Ref                     
               A/T        23/42         36             0.981 (0.614--1.569)    0.634
               A/A        2/3           22             1.935 (0.473--7.918)    
  rs2257205                                                                    
               G/G        26/41         44             Ref                     
               A/G        55/102        62             0.647 (0.403--1.039)    0.152
               A/A        16/24         48             0.891 (0.477--1.664)    
  rs2847281                                                                    
               T/T        75/129        56             Ref                     
               C/T        24/38         44             1.095 (0.690--1.739)    0.698
               C/C                                                             
  rs12456874                                                                   
               A/A        91/158        48             Ref                     
               G/A        9/12          26             1.327 (0.667--2.638)    0.415
               G/G                                                             
  rs4939827                                                                    
               C/C        72/118        48             Ref                     
               T/C        23/46         91             0.920 (0.575--1.473)    0.772
               T/T        1/1           36             1.818 (0.251--13.145)   
  rs7504990                                                                    
               C/C        60/99         44             Ref                     
               T/C        36/62         62             0.889 (0.587--1.347)    0.729
               T/T        4/9           71             0.720 (0.261--1.982)    
  rs961253                                                                     
               C/C        87/146        44             Ref                     
               A/C        13/24         68             0.928 (0.518--1.663)    0.801
               A/A                                                             
  rs2423279                                                                    
               T/T        65/117        48             Ref                     
               C/T        30/47         59             0.976 (0.632--1.508)    0.912
               C/C        0/1                                                  
  rs4925386                                                                    
               C/C        59/107        62             Ref                     
               T/C        17/25         40             1.160 (0.676--1.991)    0.608
               T/T        2/5                          0.574 (0.139--2.370)    
  rs372883                                                                     
               A/A        7/15                         Ref                     
               G/A        82/137        56             0.993 (0.457--2.159)    0.958
               G/G        1/2           11             1.331 (0.163--10.863)   
  rs455804                                                                     
               G/G        47/84         62             Ref                     
               T/G        42/69         44             1.228 (0.809--1.863)    0.126
               T/T        8/12          22             2.115 (0.989--4.520)    
  rs2014300                                                                    
               G/G        73/127        48             Ref                     0.522
               A/G        25/38         39             1.113 (0.706--1.755)    
               A/A        1/1           26             2.793 (0.385--20.276)   
  rs1547374                                                                    
               A/A        22/38         56             Ref                     
               G/A        61/106        59             0.994 (0.610--1.623)    0.330
               G/G        16/24         35             1.493 (0.777--2.866)    
  rs4822983                                                                    
               C/C        66/114        50             Ref                     
               T/C        29/45         44             1.051 (0.678--1.628)    0.976
               T/T        3/5           32             1.008 (0.312--3.257)    
  rs738722                                                                     
               C/C        17/27         66             Ref                     
               T/C        65/119        59             0.713 (0.417--1.218)    0.370
               T/T        3/4           5              1.113 (0.315--3.933)    
  rs2239815                                                                    
               C/C        34/65         56             Ref                     
               T/C        50/77         44             1.300 (0.840--2.012)    0.325
               T/T        6/11          114            1.113 (0.332--1.915)    
  rs5768709                                                                    
               G/G        18/31         59             Ref                     
               A/G        77/132        48             1.025 (0.613--1.715)    0.951
               A/A        5/7           35             1.173 (0.430--3.200)    

MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval;

Long-rank *p* values were calculated using the Chi-Square test.
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After adjusting for the various clinical factors, multivariate Cox regression analysis demonstrated that SNP genotype was an independent prognostic factor for overall survival. We identified significant correlations between two SNPs (*ADH1B* rs1229984 and *CDH1* rs9929218) and the prognosis of LC patients (Table [5](#T5){ref-type="table"}). The G/A genotype of *ADH1B* rs1229984 was associated with increased overall survival (HR, 0.537; 95% CI, 0.340--0.848; *p* = 0.008), and the A/A genotype of *CDH1* rs9929218 with reduced overall survival (HR, 6.074; 95% CI, 1.426--25.870; *p* = 0.0015).

###### Multivariate analysis of the associations between candidate SNPs and LC patient survival

  SNP ID       Genotype   HR (95% CI)             *p*
  ------------ ---------- ----------------------- -------
  rs13130787                                      
               C/C        Ref                     
               T/C        1.641 (0.975--2.760)    0.062
               T/T        1.868 (0.856--4.073)    0.116
  rs1042026                                       
               G/G        Ref                     
               A/G        0.668 (0.420--1.060)    0.087
               A/A        1.898 (0.550--6.543)    0.310
  rs1229984                                       
               A/A        Ref                     
               G/A        0.537 (0.340--0.848)    0.008
               G/G        0.352 (0.084--1.477)    0.154
  rs1000589                                       
               T/T        Ref                     
               G/T        0.773 (0.483--1.236)    0.282
               G/G        1.734 (0.999--3.010)    0.050
  rs9573163                                       
               G/G        Ref                     
               C/G        1.515 (0.958--2.394)    0.075
               C/C        1.573 (0.811--3.050)    0.180
  rs9543325                                       
               C/C        Ref                     
               T/C        0.791 (0.505--1.240)    0.307
               T/T        0.673 (0.378--1.200)    0.180
  rs944289                                        
               C/C        Ref                     
               T/C        0.831 (0.477--1.448)    0.514
               T/T        2.391 (0.513--11.139)   0.267
  rs9929218                                       
               G/G        Ref                     
               A/G        0.998 (0.637--1.565)    0.994
               A/A        6.074 (1.426--25.870)   0.015
  rs17761864                                      
               C/C        Ref                     
               A/C        0.577 (0.328--1.018)    0.058
               A/A        1.82 (0.523--6.338)     0.347
  rs4924935                                       
               T/T        Ref                     
               C/T        0.692 (0.380--1.261)    0.229
               C/C        1.334 (0.501--3.549)    0.564
  rs2257205                                       
               G/G        Ref                     
               A/G        0.783 (0.478--1.284)    0.333
               A/A        0.863 (0.454--1.642)    0.654
  rs455804                                        
               G/G        Ref                     
               T/G        1.199 (0.783--1.838)    0.404
               T/T        1.872 (0.812--4.312)    0.141

HR, hazard ratio; 95% CI, 95% confidence interval.

All *p* values were calculated using the Wald test.

A *p* \< 0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

We evaluated the effects of 37 SNPs in 26 genes on the prognosis of 170 Han Chinese male LC patients. We demonstrated that *ADH1B* rs1042026, *ADH1B* rs1229984, and *CDH1* rs9929218 were significantly associated with overall survival. Our data shed new light on the association between genetic variations in the *ADH1B* and *CDH1* genes and LC prognosis in the Han Chinese population.

The *ADH1B* gene is located on chromosome 4q21-q23. The rs1229984 variant in the *ADH1B* gene causes a missense mutation (R48H) which increases the activity of the *ADH1B* enzyme (i.e. faster acetaldehyde production generated by ethanol oxidation) \[[@R10], [@R11]\]. Following alcohol consumption, elevated ADH1B activity is thought to transiently increase the level of acetaldehyde, which leads to unpleasant effects that limit the desire to continue drinking. A meta-analysis of this variant in Asian, European, and African Americans populations (where the rs1229984 A allele is common) demonstrated a strong association with alcohol-related disorder risk \[[@R12]--[@R14]\].

The *CDH1* gene encodes the E-cadherin protein, which is a 120 kDa glycoprotein that consists of an extracellular domain containing five tandem repeats, a cytoplasmic domain, and a single transmembrane domain \[[@R15], [@R16]\]. *CDH1* hypermethylation is one of the mechanisms by which E-cadherin expression is silenced. Abnormal CDH1 expression has been linked to many human diseases including cancer, nephrolithiasis, pre-eclampsia, and ectopic pregnancy \[[@R17], [@R18]\]. Association between rs9929218 and both colorectal cancer risk and survival have also been observed \[[@R19]--[@R21]\]. Our results demonstrated that *CDH1* rs9929218 AA genotype was associated with reduced overall survival in the Chinese Han population. However, additional studies with larger cohorts derived from other populations are necessary.

Differences in survival were most apparent in individuals with T stage. There are several possible explanations for this finding. First, because individuals with T stage have already acquired many somatic mutations that could drive tumor growth or therapeutic resistance, subtle variations that alter the DNA repair capacity will not have a significant impact. Second, the differences in survival may reflect radiation-related outcomes, given that most T stage individuals received radiation treatment for the primary tumor, whereas only a minority of T stage individuals received radiation for treatment of the primary tumor. However, the latter explanation does not account for the common occurrence of relapsed metastatic disease outside the field of radiation.

In summary, our data raise the possibility that three polymorphisms may be one of major driving forces of LC progression, and could be valuable prognostic markers for LC patients. Further studies will focus on the functional experiments based on the relevant genes on animal models, to investigate detailed mechanism involved.

MATERIALS AND METHODS {#s4}
=====================

Study participants {#s4_1}
------------------

A total of 170 male patients (median age 60 years, range 32--82) who were diagnosed with LC at the First Affiliated Hospital of the Medical College of Xi\'an Jiaotong University before 2002 and who were followed-up from January 2002 to April 2013 were included in the study. All patients underwent resection for LC at the same hospital. Additionally, all patients were Han Chinese from Xi\'an city and the surrounding regions. The research protocol was performed according to the Declaration of Helsinki and was approved by the Human Research Committee of the First Affiliated Hospital of the Medical College of Xi\'an Jiaotong University for the Approval of Research Involving Human Subjects. Informed consent was obtained from all patients.

Demographic and clinical data {#s4_2}
-----------------------------

Patient demographic and clinical data including age, sex, ethnicity, residential region, smoking status, alcohol use, education status, body mass index, and family history of cancer were collected through in-person interviews using a standardized epidemiological questionnaire. Detailed clinical information including the time of diagnosis, time of surgery and/or treatment with chemotherapy, time of recurrence and/or death, tumor stage, degree of differentiation, location, whether lymph node dissection was performed, and the treatment protocol was collected through medical chart review or physician consultation. Standard follow-up was performed by a trained specialist through on-site interviews, direct calls, or written communication with either patients or family members. The most recent follow-up data in this analysis were obtained in April 2013. No patients were lost during follow-up.

SNP selection and genotyping {#s4_3}
----------------------------

We selected 37 SNPs with a minor allele frequency (MAF) \> 5% in the HapMap Han Chinese population in Beijing that were previously associated with head and neck cancer \[[@R22]--[@R24]\] for genotyping. Genomic DNA was extracted from peripheral blood leukocytes using GoldMag^®^ nanoparticles (GoldMag Ltd. Xi\'an, China) according to the manufacturer\'s instructions. DNA concentrations were estimated using a NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA). The Sequenom MassARRAY Assay Design 3.0 Software was used to design Multiplexed SNP MassEXTEND assays \[[@R25]\]. Genotyping was performed using a Sequenom MassARRAY RS1000 \[[@R25]\]. Data management and analysis were performed using the Sequenom Typer 4.0 software as previously described \[[@R25], [@R26]\].

Data analysis {#s4_4}
-------------

All follow-up survey and experimental data were analyzed using SPSS 17.0 (SPSS, Chicago, IL, USA). Survival time was defined as the time between the date of diagnosis and either the date of death (deceased patients) or last contact date (living patients). The Kaplan-Meier method was used to estimate overall survival. The survival curves were compared using Log-rank tests. Univariate analysis included the following factors: age, degree of tumor differentiation, pathologic tumor stage (pT), pathologic nodal stage (pN), WHO grade, surgical method, whether cervical lymph node dissection was performed, and the 37 candidate SNPs. Univariate and multivariable Cox proportional hazard models were used to calculate hazard ratio (HRs) and 95% confidence intervals (CIs). Two-sided *p* values \< 0.05 were considered statistically significant and were calculated using the Wald test.

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================

**CONFLICTS OF INTEREST**

The authors declare that there are no conflicts of interest.
